SCHEMBL1010764

SCHEMBL1010764

CCOC(=O)c1ccc(N2CC3CN(C(=O)OC(C)(C)C)CC3C2)nc1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.50
P2RY12 Q9H244 1/20 0.49
PDE10A Q9Y233 2/20 0.46
HDAC1 Q13547 1/20 0.44
ATM Q13315 1/20 0.44
OGA O60502 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GPR119 Q8TDV5 4/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
USP30 Q70CQ3 2/20 0.42
SGPL1 O95470 1/20 0.41
LMNA P02545 1/20 0.41
CRBN Q96SW2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011608 0.86 ACACB (0.46) PDE10AHDAC1ATMOGASMN1; SMN2
SCHEMBL2427846 0.86 P2RY12 (0.62) HRH3P2RY12ATMOGAHPGD
SCHEMBL31368898 0.84 P2RY12 (0.50) HRH3P2RY12ATMOGAHPGD
SCHEMBL8085019 0.84 P2RY12 (0.50) HRH3P2RY12ATMOGAHPGD
SCHEMBL30964849 0.82 TP53 (0.42) PDE10AHPGDSMN1; SMN2GPR119MAPT
SCHEMBL5216155 0.82 HRH3 (0.64) HRH3P2RY12HPGDSMN1; SMN2GPR119
SCHEMBL12723527 0.81 HRH3 (0.53) HRH3P2RY12PDE10AOGAUSP30
SCHEMBL22795888 0.80 PDE10A (0.50) PDE10AHDAC1GPR119USP30CRBN
SCHEMBL928501 0.80 PDE10A (0.50) PDE10AHDAC1GPR119USP30CRBN
SCHEMBL31274442 0.80 PDE10A (0.50) PDE10AHDAC1GPR119USP30CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932246-B2 Histone deacetylase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-04-26 US disclosed
US-7932246-B2 Histone deacetylase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-04-26 US disclosed
US-7932246-B2 Histone deacetylase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-04-26 US disclosed
EP-1881977-B1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2011-01-05 EP disclosed
EP-1881977-B1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2011-01-05 EP disclosed
US-20100152155-A1 Histone Deacetylase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2010-06-17 US disclosed
US-20100152155-A1 Histone Deacetylase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2010-06-17 US disclosed
US-20100152155-A1 Histone Deacetylase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2010-06-17 US disclosed
EP-1881977-A1 HISTONE DEACETYLASE INHIBITORS Chroma Therapeutics Limited (GB) 2008-01-30 EP disclosed
WO-2006123121-A1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-23 WO disclosed
WO-2006123121-A1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152155-A1 Histone Deacetylase Inhibitors HDAC1, HDAC2, HDAC11 HRH3 599/4885P2RY12 4870/4885PDE10A 4784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.